Mowery & Schoenfeld Wealth Management LLC Increases Stock Position in Merck & Co., Inc. (NYSE:MRK)

Mowery & Schoenfeld Wealth Management LLC raised its position in Merck & Co., Inc. (NYSE:MRK) by 47.5% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 379 shares of the company’s stock after buying an additional 122 shares during the period. Mowery & Schoenfeld Wealth Management LLC’s holdings in Merck & Co., Inc. were worth $43,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Brookstone Capital Management raised its stake in shares of Merck & Co., Inc. by 7.1% during the 1st quarter. Brookstone Capital Management now owns 64,476 shares of the company’s stock worth $8,508,000 after buying an additional 4,296 shares during the period. Future Financial Wealth Managment LLC purchased a new position in Merck & Co., Inc. during the first quarter valued at $106,000. Sovereign Financial Group Inc. grew its position in shares of Merck & Co., Inc. by 12.3% in the first quarter. Sovereign Financial Group Inc. now owns 4,905 shares of the company’s stock valued at $647,000 after purchasing an additional 539 shares during the period. Sunpointe LLC increased its stake in shares of Merck & Co., Inc. by 9.8% during the first quarter. Sunpointe LLC now owns 4,539 shares of the company’s stock worth $602,000 after purchasing an additional 407 shares in the last quarter. Finally, GoalVest Advisory LLC raised its position in shares of Merck & Co., Inc. by 5.3% during the 1st quarter. GoalVest Advisory LLC now owns 11,659 shares of the company’s stock worth $1,538,000 after purchasing an additional 590 shares during the last quarter. Institutional investors and hedge funds own 76.07% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $155.00 price objective on shares of Merck & Co., Inc. in a report on Thursday, October 3rd. Truist Financial decreased their price objective on Merck & Co., Inc. from $143.00 to $132.00 and set a “buy” rating on the stock in a report on Wednesday, October 9th. UBS Group dropped their target price on shares of Merck & Co., Inc. from $142.00 to $136.00 and set a “buy” rating for the company in a report on Wednesday, October 9th. Wells Fargo & Company decreased their price target on shares of Merck & Co., Inc. from $140.00 to $125.00 and set an “equal weight” rating on the stock in a research note on Wednesday, July 31st. Finally, Morgan Stanley upped their price objective on shares of Merck & Co., Inc. from $132.00 to $134.00 and gave the company an “equal weight” rating in a research note on Thursday, July 11th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, nine have given a buy rating and four have given a strong buy rating to the company. According to data from MarketBeat, Merck & Co., Inc. presently has a consensus rating of “Moderate Buy” and an average price target of $131.62.

Merck & Co., Inc. Trading Down 0.7 %

MRK traded down $0.75 during trading hours on Thursday, reaching $105.63. The company’s stock had a trading volume of 2,163,575 shares, compared to its average volume of 8,761,672. The stock has a market cap of $267.54 billion, a PE ratio of 117.92, a P/E/G ratio of 1.55 and a beta of 0.39. Merck & Co., Inc. has a fifty-two week low of $99.80 and a fifty-two week high of $134.63. The company has a debt-to-equity ratio of 0.80, a current ratio of 1.47 and a quick ratio of 1.22. The business’s 50-day moving average is $113.86 and its 200-day moving average is $121.93.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings results on Tuesday, July 30th. The company reported $2.28 EPS for the quarter, beating the consensus estimate of $2.16 by $0.12. The business had revenue of $16.10 billion for the quarter, compared to analyst estimates of $15.87 billion. Merck & Co., Inc. had a return on equity of 40.69% and a net margin of 21.99%. The company’s quarterly revenue was up 7.1% on a year-over-year basis. During the same quarter in the prior year, the company posted ($2.06) EPS. As a group, equities research analysts predict that Merck & Co., Inc. will post 7.88 earnings per share for the current fiscal year.

Merck & Co., Inc. Profile

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.